Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary
- 1 July 1989
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 25 (7), 1053-1055
- https://doi.org/10.1016/0277-5379(89)90387-8
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Adenocarcinoma of Unknown Primary OriginSouthern Medical Journal, 1981
- Preliminary report on the efficacy of sequential methotrexate and 5-fluorouracil in advanced breast cancerCancer, 1981
- 5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric CancerAnnals of Internal Medicine, 1980
- Enhanced 5-Fluorouracil Nucleotide Formation After Methotrexate Administration: Explanation for Drug SynergismScience, 1979
- Identifying the Primary Site in Metastatic Cancer of Unknown OriginPublished by American Medical Association (AMA) ,1979
- Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil responseBiochemical Pharmacology, 1978
- Metastatic Carcinomas from Occult Primary TumorsAnnals of Surgery, 1977
- Treatment of the patient with adenocarcinoma of unknown originCancer, 1972
- Metastatic cancer of unknown primary siteCancer, 1970